THOUSAND
OAKS, Calif., Aug. 13,
2024 /PRNewswire/ -- Concept Matrix Solutions, Inc.
("CMS") or the ("Company"), a privately held vertically integrated
biotechnology company dedicated to developing and manufacturing
innovative delivery forms in both pharmaceutical and nutraceutical
spaces today announced that it has received patent issuance from
the U.S. Patent Office (USPTO) regarding U.S. Patent No. 11,766,445
for its "Oral Soft Gel Capsule Containing Psychedelic Compound".
This patent marks a significant milestone in the company's efforts
to develop more effective treatments for mental health disorders
and chronic pain conditions.
Concept Matrix Solutions, Inc. Receives
Patent Approval for its Oral Soft Gel Capsule Containing
Psychedelic Compound.
The newly patented soft gel capsule technology offers several
advantages over traditional delivery methods which allows for
improved rate and extent of absorption, and the reduced variability
per dosage, potentially leading to more consistent and effective
dosing. Furthermore, encapsulation process helps protect the
psychedelic compound from degradation, potentially extending shelf
life and maintaining potency. Soft gel capsules are easy to swallow
and can be taken discreetly, improving patient compliance and
comfort.
Rob Davidson, Chief Technology
Officer at CMS, commented on the patent issuance: "This new
delivery method represents a significant advancement in psychedelic
medicine. By improving bioavailability and ease of use, we believe
our soft gel capsules will help more patients benefit from the
therapeutic potential of psychedelics."
The development of novel dose forms for psychedelic compounds
comes at a critical time, as mental health disorders and chronic
pain conditions continue to affect millions of people worldwide.
Recent studies have shown promising results for the use of
psychedelics in treating anxiety, post-traumatic stress disorder
(PTSD), obsessive-compulsive disorder (OCD), and various forms of
chronic pain.
Tony LaRosa, Chief Executive
Officer at CMS, commented, "There is an urgent need for more
effective treatments for these challenging conditions, traditional
pharmaceuticals often fall short in providing long-lasting relief,
and many patients struggle with side effects or develop tolerance.
Our research suggests that psychedelic compounds, when properly
administered, may offer a new paradigm in mental health and pain
management."
XYZ Pharmaceuticals is currently conducting clinical trials to
evaluate the safety and efficacy of its psychedelic soft gel
capsules for the treatment of anxiety, PTSD, OCD, and chronic pain.
The company expects to release preliminary results later this
year.
For more information about XYZ Pharmaceuticals and its research
initiatives, please visit www.xyzpharma.com.
About XYZ Pharmaceuticals
XYZ Pharmaceuticals is a clinical-stage biopharmaceutical
company dedicated to developing innovative treatments for mental
health disorders and chronic pain conditions. By leveraging
cutting-edge research in psychedelic medicine and novel drug
delivery technologies, XYZ Pharmaceuticals aims to improve patient
outcomes and quality of life.
*This press release contains forward-looking statements subject
to risks and uncertainties that could cause actual results to
differ materially from those projected.*
an oral soft gel capsule for treatment for anxiety, wherein
anxiety is associated with at least one of obsessive compulsive
disorder (OCD), pain, irritability, fibromyalgia, post-traumatic
stress disorder (PTSD), cluster headaches, paranoia, psychosis,
anxiety, panic attacks, flashbacks, smoking addiction, alcohol
addiction, and cocaine addiction.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/concept-matrix-solutions-receives-patent-approval-for-its-oral-soft-gel-capsule-containing-psychedelic-compound-302221287.html
SOURCE CONCEPT MATRIX SOLUTIONS